Virus Seed Bank Purity Testing

Overview Methods Regulatory Advantages FAQ

Overview

Virus seed bank purity testing is a core quality control service for master and working virus seed banks. It provides a comprehensive, quantitative purity assessment to ensure compliance with release standards for vaccine and gene therapy production.

Under ICH Q6B, impurity control is a critical component of specification setting for biotechnological products. For virus seed banks, purity testing targets all non‑target viral particles, including host cell protein residuals, host cell DNA residuals, and non‑functional viral particles such as empty capsids and partially filled capsids. The FDA classifies empty or non‑infectious viral particles as impurities because they affect dosing accuracy and induce non‑specific immunogenicity and product efficacy variability.

This service covers three core purity dimensions:

Host cell protein residuals: SDS PAGE with silver or Coomassie staining to visualize impurity protein bands
Host cell DNA residuals: qPCR/ddPCR absolute quantification to evaluate DNA clearance by upstream purification
Empty/partial capsid ratio: TEM direct visualization (reference method) and AEX HPLC high-resolution quantification

Creative Biogene provides complete purity testing from viral seed bank establishment to release, following the ICH Q6B impurity control framework with orthogonal multi‑platform strategies (SDS‑PAGE, HPLC, TEM). Data are ready for IND/BLA CMC sections.

Technical Principles

Impurity Sources and Risks

Impurity Type	Source	Risk	Key Testing Focus
Host cell protein residuals	Cell lysis (HEK293, Vero, CHO, etc.)	Immunogenicity affects viral function	Total protein, capsid purity, and impurity bands
Host cell DNA residuals	Residual genomic DNA from lysed cells	Potential oncogenicity; infectivity	Total DNA amount; fragment size distribution
Empty/partially filled capsids	Inefficient viral packaging (AAV, lentivirus, etc.)	Reduces dosing accuracy; induces non‑specific immune responses	Full/empty capsid ratio

In some AAV production systems (e.g., HEK293 transient transfection), empty capsids can account for 50‑90% of total AAV particles. The FDA classifies these non‑functional particles as impurities.

SDS‑PAGE

Separates proteins by molecular weight under denaturing and reducing conditions. Silver staining detects ng‑level impurities. Visualizes capsid protein purity and host cell protein impurity bands. Supports semi‑quantitative assessment by densitometry.

HPLC – Empty/Full Capsid Ratio

Anion exchange chromatography separates full and empty capsids based on surface charge differences caused by packaged DNA. High‑resolution IEX can achieve resolution of up to 15 for AAV8. Dual‑wavelength detection (260 nm for DNA, 280 nm for protein) with a 260/280 ratio confirms filling status. Linear over a wide concentration range (E+9 to E+13 vp/mL, R² >0.98).

TEM – Direct Visualization

Negative staining (uranyl acetate) allows direct observation of virus particles. Empty capsids show lower electron density in the core; full capsids appear electron dense. Count at least 200 particles to calculate the empty/full ratio. Provides orthogonal verification for HPLC results.

Host Cell Protein Residuals

ELISA – Quantitative total host protein (ng/mg viral protein) using cell line‑specific kits
SDS‑PAGE with silver stain – Qualitative impurity protein profiling
LC‑MS/MS – Identification of specific host proteins (high‑risk species)

Host Cell DNA Residuals (qPCR/ddPCR)

Targets host genomic repetitive sequences (Alu, LINE‑1) or single‑copy genes. qPCR provides rapid quantification; ddPCR eliminates the standard curve requirement and offers high precision for low‑abundance residuals. Sensitivity down to 1 pg/reaction.

Regulatory Basis

Document	Key Requirement
ICH Q6B	Core framework for impurity control; covers process‑related and product‑related impurities with test procedures and acceptance criteria.
ICH Q5A(R2)	Viral safety evaluation; emphasizes titer and purity (R2 update).
USP <1047>	Risk‑based CQA control framework for gene therapy products.
FDA CGT Guidance (2020)	CMC information for IND submissions.
WHO TRS 978, Annex 3	Cell substrate evaluation; purity assessment required for virus seed banks.

Creative Biogene's Advantages

ICH Q6B‑aligned impurity framework – Orthogonal multi‑platform strategy ensures comprehensive and accurate purity assessment.
Dual‑platform empty/full capsid testing – AEX‑HPLC provides high‑resolution quantification; TEM provides direct visual verification.
High‑resolution AEX‑HPLC – Resolution up to 15; linear from E+9 to E+13 vp/mL (R² >0.98); shorter sample processing time.
QuTEM enhanced TEM – Quantitative electron microscopy distinguishes full, partial, and empty capsids; correlates with mass photometry and AUC.
Multi‑method host protein coverage – SDS‑PAGE with silver stain (qualitative), ELISA (quantitative), LC‑MS/MS (high‑risk protein identification).
High‑sensitivity host DNA detection – qPCR/ddPCR sensitivity down to 1 pg/reaction; ddPCR eliminates standard curve.
Broad virus coverage – AAV, adenovirus, lentivirus, retrovirus, herpesvirus, poxvirus, and vaccine viruses.

FAQ

Q1: Is empty/full capsid testing mandatory for virus seed bank purity?

A: For viruses prone to empty capsid formation (e.g., AAV), yes. The FDA classifies empty or non‑infectious viral particles as impurities because they affect dosing accuracy and induce non‑specific immunogenicity. In AAV systems, empty capsids can account for 50‑90% of total particles. We recommend AEX‑HPLC combined with TEM for orthogonal confirmation.

Q2: How to choose among SDS‑PAGE, HPLC, and TEM? Are all three necessary?

A: Each addresses different dimensions. SDS‑PAGE assesses capsid protein purity and impurity protein profiles (qualitative or semi‑quantitative). AEX‑HPLC quantifies full/empty capsid ratio (high throughput, quantitative). TEM provides direct visualization and detects partially filled capsids. Recommended strategy: AEX‑HPLC as primary release method, SDS‑PAGE for protein purity, TEM for orthogonal verification.

Q3: What is the principle of AEX‑HPLC for empty/full capsid separation?

A: Full capsids (DNA‑containing) and empty capsids have subtle surface charge differences due to packaged DNA. Under a salt gradient, they elute at different salt concentrations, forming two separate peaks. High‑resolution IEX can achieve a resolution of 15 for AAV8. Dual‑wavelength detection (260 nm for DNA, 280 nm for protein) with a 260/280 ratio confirms filling status.

Q4: SDS‑PAGE silver stain shows multiple impurity bands, but the ELISA total host protein is very low. Why?

A: Possible reasons: (1) Silver stain is extremely sensitive and can detect proteins below ELISA LOQ; (2) Bands may represent capsid degradation products (product‑related impurities) rather than host proteins; (3) ELISA antibody may not recognize certain host protein species (coverage issue). Recommendation: Perform LC‑MS/MS to identify the impurity bands.

Q5: Does ICH Q6B directly apply to virus seed bank purity testing?

A: ICH Q6B primarily addresses protein and peptide products and does not provide detailed technical requirements for viral vectors. For virus seed banks, purity testing follows ICH Q6B impurity control principles combined with industry practice, USP <1047>, and FDA CGT Guidance. The combination of SDS‑PAGE, HPLC, TEM, ELISA, and qPCR has become the standard. We recommend clearly stating the method selection rationale and validation status in IND submission documents.

* For research use only. Not intended for any clinical use.

Quick Inquiry